Volume 16, Issue 4, Pages (April 2008)

Slides:



Advertisements
Similar presentations
Volume 19, Issue 2, Pages (February 2011)
Advertisements

Volume 19, Issue 1, Pages (January 2011)
Volume 15, Issue 6, Pages (June 2007)
Volume 3, Issue 5, Pages (May 2001)
Volume 16, Issue 3, Pages (March 2008)
Volume 24, Issue 7, Pages (July 2016)
Comparative clonal analysis of reconstitution kinetics after transplantation of hematopoietic stem cells gene marked with a lentiviral SIN or a γ-retroviral.
Molecular Therapy - Nucleic Acids
Self-Excising Retroviral Vectors Encoding the Cre Recombinase Overcome Cre- Mediated Cellular Toxicity  Daniel P. Silver, David M. Livingston  Molecular.
Volume 24, Issue 7, Pages (July 2016)
Volume 17, Issue 11, Pages (November 2009)
Volume 25, Issue 3, Pages (March 2017)
Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer by Andrew Wilber,
Volume 17, Issue 9, Pages (September 2009)
Volume 17, Issue 8, Pages (August 2009)
Volume 15, Issue 1, Pages (January 2007)
Volume 14, Issue 4, Pages (October 2006)
Transient Gene Expression by Nonintegrating Lentiviral Vectors
Volume 20, Issue 5, Pages (May 2012)
Molecular Therapy - Oncolytics
Volume 23, Issue 5, Pages (May 2015)
Volume 10, Issue 1, Pages (July 2004)
Transduction of Human Embryonic Stem Cells by Foamy Virus Vectors
Volume 12, Issue 3, Pages (September 2005)
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Expression of the MOZ-TIF2 oncoprotein in mice represses senescence
Volume 9, Issue 4, Pages (April 2004)
Jun Zhan, Irudayam Maria Johnson, Matthew Wielgosz, Arthur W Nienhuis 
Volume 17, Issue 2, Pages (February 2009)
Volume 20, Issue 10, Pages (October 2012)
Volume 19, Issue 3, Pages (March 2011)
Volume 15, Issue 5, Pages (May 2007)
Volume 15, Issue 9, Pages (September 2007)
Kailin Xu, Hong Ma, Thomas J. McCown, Inder M. Verma, Tal Kafri 
Volume 19, Issue 2, Pages (February 2011)
Volume 12, Issue 5, Pages (November 2005)
Inclusion of jaagsiekte sheep retrovirus proviral elements markedly increases lentivirus vector pseudotyping efficiency  Patrick L. Sinn, Erin R. Burnight,
Volume 10, Issue 4, Pages (October 2004)
Volume 133, Issue 4, Pages (May 2008)
Volume 19, Issue 4, Pages (April 2011)
RNA Polymerase II Activity of Type 3 Pol III Promoters
Volume 15, Issue 8, Pages (August 2007)
Volume 15, Issue 11, Pages (November 2007)
Molecular Therapy - Nucleic Acids
Volume 15, Issue 4, Pages (April 2007)
Retroviral Pseudotransduction for Targeted Cell Manipulation
Volume 21, Issue 8, Pages (August 2013)
Volume 19, Issue 5, Pages (May 2011)
Volume 11, Issue 6, Pages (June 2005)
Volume 18, Issue 4, Pages (April 2010)
Molecular Therapy - Nucleic Acids
Rodney P. DeKoter, Hyun-Jun Lee, Harinder Singh  Immunity 
Volume 18, Issue 9, Pages (September 2010)
Kristoffer Weber, Udo Bartsch, Carol Stocking, Boris Fehse 
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Nucleic Acids
Volume 17, Issue 11, Pages (November 2009)
Volume 3, Issue 4, Pages (April 2001)
Volume 2, Issue 4, Pages (October 2000)
Volume 23, Issue 4, Pages (April 2015)
Volume 9, Issue 2, Pages (February 2004)
Volume 19, Issue 1, Pages (January 2011)
Volume 9, Issue 5, Pages (May 2004)
Volume 33, Issue 1, Pages (July 2010)
Volume 11, Issue 5, Pages (May 2005)
A Double-Switch Vector System Positively Regulates Transgene Expression by Endogenous microRNA Expression (miR-ON Vector)  Mario Amendola, Alice Giustacchini,
Volume 14, Issue 1, Pages (July 2006)
Volume 15, Issue 10, Pages (October 2007)
Volume 17, Issue 2, Pages (February 2009)
Presentation transcript:

Volume 16, Issue 4, Pages 718-725 (April 2008) Physiological Promoters Reduce the Genotoxic Risk of Integrating Gene Vectors  Daniela Zychlinski, Axel Schambach, Ute Modlich, Tobias Maetzig, Johann Meyer, Elke Grassman, Anjali Mishra, Christopher Baum  Molecular Therapy  Volume 16, Issue 4, Pages 718-725 (April 2008) DOI: 10.1038/mt.2008.5 Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 1 Transient transfection assays reveal low enhancer activity of cellular promoters and reduced enhancer activity of self-inactivating (SIN) vector in comparison with long-terminal repeat (LTR) vectors. (a) The reporter construct encodes a codon-optimized luciferase that is devoid of at least 300 known transcription factor binding sites. A synthetic polyadenylation (syn. pA) prevents potential readthrough from the enhancer–promoter cassette (Enh-P) cloned downstream of the termination site of the luciferase cassette. Alternatively, entire provirus sequences of LTR or SIN vectors were introduced in sense or antisense orientation. (b) Schema of transcription factor binding sites predicted by computer algorithms and functional data, revealing a dense clustering of binding sites in the SFFV-U3 region, in contrast to the cellular promoter elongation factor-1α (EF1α). (c) The retroviral Enh-P sequences derived from myeloproliferative sarcoma virus (MPSV) and spleen focus–forming virus (SFFV) show a significant induction of two different minimal promoters, in contrast to the cellular promoters [EFS and phosphoglycerate kinase (PGK)]. No, lack of Enh-P 3′ of the luciferase cassette. Error bars indicate standard deviations of four experiments. (d) When compared with LTR vectors, SIN vectors show a greatly decreased enhancer activity, even when they contain the same Enh-P. Enhancer activity is also more dependent on orientation (sense or antisense to the luciferase cassette) in the SIN configuration. CMV, cytomegalovirus; EGFP, enhanced green fluorescent protein; no, SIV vector lacking an interval Enh-P TK, thymidine kinase; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element. Molecular Therapy 2008 16, 718-725DOI: (10.1038/mt.2008.5) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 2 Stably integrated “minigene” reporter constructs reveal the low enhancer activity of the cellular promoters tested. (a) The retroviral self inactivating (SIN) vector contains a minigene cassette in the U3 region of the long-terminal repeat (LTR), consisting of a minimal promoter followed by a truncated CD34 surface marker gene (tCD34). Termination is mediated by signals in the R region of the LTR. The same vectors were also tested with 1×HS4 insulator element inserted upstream of the minigene cassette. Enh-P sequences were introduced as indicated. A control vector contained no minimal promoter (ΔCMV). (b) In SC1 fibroblasts and lineage-negative primary murine hematopoietic cells, only the internal spleen focus–forming virus (SFFV) promoter led to a significant activation of the minigene cassette. Background levels are reflected in the tCD34 expression of the construct that lacks a minimal promoter. Data obtained from SC1 cells are shown in white columns and lineage-negative cells in grey ones. The insets show representative flow cytometry data (SC1 cells) for illustration of the assay, CD34 expression shown on the y-axis. Potential activation of the minigene by transcriptional readthrough could be ruled out (Supplementary Figure S2). CMV, cytomegalovirus; EFS, short form of EF1α EGFP, enhanced green fluorescent protein; PGK, phosphoglycerate kinase. Molecular Therapy 2008 16, 718-725DOI: (10.1038/mt.2008.5) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 3 The clonal dominance assay shows a significant reduction in transformed cells following the use of a self-inactivating (SIN) vector with a physiological cellular promoter (EFS). The ratio of replating frequency (determined by limiting dilution cloning) per vector copy number (detected by real-time PCR) 4 days after transduction, is a measure of the degree of transformation. A SIN vector with an internal EFS promoter shows no transforming capacity. The efficiency of transformation is significantly reduced in comparison to an unmodified or insulated SIN vector with an internal retroviral promoter. All seven experiments conducted with SIN.EFS vectors yielded results that were below the detection limit, indicated as a horizontal line. For negative values, calculations are based on the assumption that a replating clone would have been detected when plating 97 instead of 96 wells. Molecular Therapy 2008 16, 718-725DOI: (10.1038/mt.2008.5) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 4 Self-inactivating (SIN) vectors containing an internal retrovirus-derived enhancer–promoter (SF) and insulator sequences (HS4 250 base pair core element) in the otherwise deleted U3 region of the long-terminal repeat. (a) The vector with a single copy of the HS4 element (SIN.SF.GFP.1×HS4) has identical titers and expression levels (in SC1 fibroblasts) as the unmodified counterpart (SIN.SF.GFP) does. In contrast, a vector with a tandem repeat of the HS4 element had significantly reduced titers, indicative of genetic instability (SIN.SF.GFP.2xHS4). (b) Histogram of enhanced green fluorescent protein (EGFP) expression achieved with the different vectors under similar multiplicity of infection (SC1 fibroblasts). Differences in the replating frequency cannot be explained by variations in EGFP expression levels. t.u., transducing units. Molecular Therapy 2008 16, 718-725DOI: (10.1038/mt.2008.5) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 5 Molecular characterization of cultures and replating clones. (a) Southern blot analysis of replating clones shows multiple vector insertion sites when using vectors SIN.SF.GFP or SIN.SF.GFP.1×HS4. (b) Northern blot revealing transcriptional upregulation of Evi1 in replating clones. Mock-transduced Lin− bone marrow cells cultured for >14 days served as negative control, and 18S RNA served as loading control. (c) Induction of Evi1 transcripts can be detected as early as 6 days after gene transfer, thereby suggesting a quick outgrowth of mutants. In contrast, cultures transduced with a vector containing the EFS internal promoter showed no detectable induction of Evi1 at any of the time points. MOI, multiplicity of infection; SIN, self-inactivating. Molecular Therapy 2008 16, 718-725DOI: (10.1038/mt.2008.5) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 6 Cytology of cultures before replating (May-Grünwald–Giemsa stain of cytospin preparations). Mock-treated and SIN.EFS-transduced cultures both show a predominance of mature myeloid cells, whereas numerous blasts are present in cultures transduced with vectors SIN.SF.GFP or SIN.SF.GFP.1×HS4. SIN, self-inactivating. Molecular Therapy 2008 16, 718-725DOI: (10.1038/mt.2008.5) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions